Coya Therapeutics, Inc. is a clinical-stage biotechnology firm based in Houston, Texas, specializing in the development of advanced therapies aimed at enhancing regulatory T cell (Treg) functionality for the treatment of autoimmune and neurodegenerative diseases. The company is advancing a robust pipeline through its proprietary platform, targeting critical illnesses such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis. With its innovative approach and ongoing clinical trials, Coya is poised to deliver transformative therapies that address significant unmet medical needs and could redefine immune-mediated treatment paradigms in the future. Show more
Location: 5850 SAN FELIPE ST., HOUSTON, TX, UNITED STATES, 77057, Houston, TX, 77057, USA | Website: https://coyatherapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
97.3M
52 Wk Range
$3.94 - $8.29
Previous Close
$4.60
Open
$4.68
Volume
292,996
Day Range
$4.50 - $4.85
Enterprise Value
69.17M
Cash
28.13M
Avg Qtr Burn
-1.131M
Insider Ownership
5.69%
Institutional Own.
24.52%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
COYA 301 (Low Dose IL-2) Details Alzheimer's disease, Neurodegenerative disease | Phase 2 Data readout | |
COYA 302 Details Amyotrophic lateral sclerosis | Phase 2 Data readout | |
COYA 302 (Low Dose IL-2 + CTLA4-Ig) Details Frontotemporal dementia | Phase 2 Initiation |